Kosan’s Motilin Receptor Agonist Enters Phase I Clinical Trial
Kosan Biosciences announced that Pfizer has initiated a Phase I clinical trial of motilin receptor agonist PF-04548043, formerly KOS-2187, for the treatment of gastroesophageal reflux disease and potentially other gastrointestinal (GI) disorders.
The Phase I clinical trial is designed to test the safety, tolerability and pharmacokinetics of PF-04548043 in healthy subjects, Kosan said.
In December 2006, Kosan and Pfizer established a worldwide license agreement for Kosan’s motilin agonist program, including KOS-2187 and related compounds, in a transaction potentially valued at $250 million, according to the company.
The company added that in preclinical studies, PF-04548043 showed an improved safety profile relative to erythromycin and accelerated gastric emptying, suggesting that it may provide symptom relief in several GI diseases.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May